January 17, 2020

Office of the Vermont Attorney General
109 State Street
Montpelier, VT 05609

Re: New High-Cost Prescription Drugs Reporting

Dear Office of the Vermont Attorney General,

In compliance with 18 V.S.A. § 4637, Amneal Pharmaceuticals LLC ("Amneal") has introduced new generic prescription drugs ("Products") at a wholesale acquisition cost that is over the threshold set for a specialty drug under the Medicare Part D program, which is attached as Exhibit A. This letter also provides the additional required information by 18 V.S.A. § 4637(c) regarding the Product. Amneal notes that the Office of the Attorney General has not yet prescribed a format for submissions under this section. Further, as authorized by 18 V.S.A. § 4637(d), Amneal has limited the information reported to that which is in the public domain or publicly available.

(1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;

This drug is a generic product, therefore no marketing and pricing plans are available. This Product is sold in the United States only.

(2) The estimated volume of patients who may be prescribed the drug;

The estimated average number of patients per month is unknown to Amneal.

(3) Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval;

Not applicable.

(4) The date and price of acquisition if the drug was not developed by the manufacturer;

Amneal did not acquire this product.

Regards,

Leslie Restaino
VP, Chief Compliance Officer

EXHIBIT A

NDC	PRODUCT	DATE OF INTRO TO MARKET	WAC
69238173102	Pyridostigmine Bromide Oral Solution 60mg/5mL	1/17/2020	1071.54